(NASDAQ GS: TCDA)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Tricida, Inc. ("Tricida" or the "Company") on behalf of stockholders. A class action complaint has been filed against Tricida. The complaint alleges that defendants made materially false and misleading statements and omissions of material facts about Tricida's attempts to gain approval from the United States Food and Drug Administration ("FDA") for its lead investigational drug candidate, veverimer. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Tricida's New Drug Application ("NDA") for veverimer was materially deficient; (ii) accordingly, it was foreseeably likely that the FDA would not accept the NDA for veverimer; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.